UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange
Act of 1934
Date of Report: April 25, 2017
Commission
File Number: 001-36891
Cellectis S.A. |
(Exact Name of registrant as specified in its charter) |
8, rue de la Croix Jarry |
75013 Paris, France |
+33 1 81 69 16 00 |
(Address of principal executive office) |
Indicate by
check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form
20-F ☑
Form 40-F ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
EXHIBIT INDEX
Exhibit |
Title |
|
99.1 |
Press release, dated April 25, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CELLECTIS S.A. |
||
(Registrant) | ||
April 25, 2017 |
By: |
/s/ André Choulika |
André Choulika |
||
|
Chief Executive Officer |
3
Exhibit 99.1
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
NEW YORK--(BUSINESS WIRE)--April 25, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that data on its gene-edited allogeneic off-the-shelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.
Oral presentation:
Development of Gene Edited Allogeneic CAR T-Cell Therapy
Philippe
Duchateau, PhD. Chief Executive Officer, Cellectis
Session: 300 - Clinical Advancement of Gene Editing-Moving New Science
to the Clinic - Organized by the Clinical Trials and Regulatory Affairs
Committee
Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST
Lincoln 2, 3, 4
Poster presentations:
176 - Genome-Wide Analysis of TALEN® Activity in Primary Cells
Brian
Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent
Poirot
Session: Gene Targeting and Gene Correction I
Wednesday May 10, 2017
at 5:30 PM EST
Exhibit Hall A & B South
114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia
Targeting CD22 with CAR T-cells
Anne-Sophie Gautron,
Cécile Schiffer-Mannioui, Alan Marechal, Severine Thomas, Agnes Gouble,
Laurent Poirot, Julianne Smith
Session: Cancer-Immunotherapy, Cancer Vaccines I
Wednesday May 10,
2017 from 5:30 PM to 7:30pm EST
Exhibit Hall A & B South
372 - Manufacturing of Gene-Modified Mouse CAR T-Cells
Laurent
Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau
Session: Gene Targeting and Gene Correction II
Thursday May 11, 2017
from 5:15 PM to 7:15 PM EST
Exhibit Hall A & B South
About Cellectis
Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 17 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases as well as its pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Cellectis Group
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
CONTACT:
Media:
Jennifer Moore, 917-580-1088
VP of
Communications
media@cellectis.com
or
Caitlin Kasunich,
212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
or
IR:
Simon
Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com